Navigation Links
Actos Lawsuit Filed by Wright & Schulte LLC Contends NY Man Developed Bladder Cancer after Taking the Type II Diabetes Medication
Date:7/21/2014

Columbus, OH (PRWEB) July 21, 2014

The defective drug attorneys at Wright & Schulte LLC have filed an Actos lawsuit on behalf of a Schenectady, New York man who alleges that he developed bladder cancer as a result of taking Actos for more than a year to treat his Type II diabetes. According to the Actos lawsuit, the New York man’s doctor prescribed Actos in September 2003, and in 2010 he was diagnosed with bladder cancer. The lawsuit also contends, that as a result of taking the diabetes medication, the man suffered permanent and severe injuries, including having to undergo multiple surgeries and the removal of one of his kidneys. This Actos bladder cancer lawsuit was filed in the Circuit Court of Cook County, Illinois, on June 12, 2014 (Case No. 2014-L-006265)

In addition to the New York man, the attorneys at Wright & Schulte LLC are currently representing other clients in pending Actos lawsuits, and are currently offering free case evaluations to people who believe they have experienced serious side-effects caused by Actos or other harmful prescription drugs. To speak with an experienced defective drug attorney contact Wright & Schulte LLC by calling 1-800-399-0795 or visit http://www.yourlegalhelp.com. You can also like us on Facebook and Follow us on Twitter for all the current news on Actos and other drug side-effects.

Wright & Schulte further contends in this Actos lawsuit that the defendant, Takedea Pharmaceuticals America Inc., knew that taking the prescription medication can cause bladder cancer but did not adequately inform doctors and patients about the potential risk of developing bladder cancer after taking Actos. The Actos bladder cancer complaint further purports that as one of Takeda’s top selling drugs, Actos had global sales of $4.8 billion within the last year and accounted for approximately 27 percent of Takeda’s revenue.

The American Diabetes Association in 2011 published a study that examined the link between Actos, generically known as pioglitazone, and the risk of bladder cancer. The study compared patients treated with pioglitazone with patients who did not use pioglitazone. Researchers found an increased risk of cancer in patients who used pioglitazone for more than two years. Additionally, the study noted that 95 percent of the diagnosed cancers among pioglitazone users were detected at an early stage. A post hoc analysis suggests further increased risk of bladder cancer with even longer periods of exposure to pioglitazone.
[care.diabetesjournals.org/content/34/4/916.full, April 2011]

After the study was published, the U.S. Food & Drug Administration (FDA), issued a warning about Actos, which was approved in 1999 to treat Type II diabetes. The FDA warned in June 2011 that using Actos for more than one year may be associated with an increased risk of bladder cancer. The federal regulator also mentioned reviewing a study conducted in France that focused on 1.5 million patients with diabetes who were followed from 2006 to 2009. The results showed a statistically significant increase in the risk for bladder cancer in males who took pioglitazone compared to other patients exposed to other anti-diabetic drugs. As a result of the study, the FDA noted that sales of Actos was suspended in France and Germany recommended not to start new patients on pioglitazone. Sales of the diabetic medication were not suspended in the United States.
[fda.gov/drugs/drugsafety/ucm259150.htm, June 15, 2011]
[ema.europa.eu/docs/en_GB/document_library/Press_release/2011/06/WC500107515.pdf, June 9,2011]

In April of this year, a federal jury in Louisiana awarded $9 billion in punitive damages in Actos bladder cancer lawsuit, agreeing with the plaintiffs that the makers of Actos, Takeda Pharmaceuticals U.S.A. Inc. and Eli Lilly & Co. did not disclose the cancer risk associated with taking the medication and ordered Takeda to pay $6 billion and Lilly to pay $3 billion. The lawsuit against Takeda and Lilly was filed in the U.S. District Court for the Western District of Louisiana (case no. 11-md-02299). There are currently over 3,055 Actos lawsuit claims pending litigation in the U.S. District Court for the Western District of Louisiana (MDL 2299). All of the complaints filed on behalf of individuals who used Actos allege one or more serious side effects, including bladder cancer, heart failure and liver problems as a result of using the prescribed diabetic medication.

About Wright & Schulte LLC
Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free Actos lawsuit case evaluations and other harmful drug lawsuit evaluations are available through yourlegalhelp.com or by calling 1-800-399-0795.

Contact:
Wright & Schulte LLC
812 East National Road
Vandalia, Ohio 45377
1-800-399-0795
http://www.yourlegalhelp.com
Like us on Facebook
Follow us on Twitter
Join us on Google+

Read the full story at http://www.prweb.com/releases/2014/07/prweb12023380.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Claim that raw milk reduces lactose intolerance doesnt pass smell test, study finds
2. Universal Treatment and Recovery Center Treats Lactose Intolerance
3. Actos Lawsuit News: Nation’s Third Actos Trial Involving Bladder Cancer Allegations Now Underway in Nevada State Court, Bernstein Liebhard LLP Reports
4. Actos Bladder Cancer Allegations Attorney Help: Resource4thePeople Comments on Progress of Federal Litigation Involving Cancer Claims Filed against Takeda Pharmaceuticals
5. Actos Bladder Cancer Allegation Lawyer: Resource4thePeople Reports New Cases Involving Cancer Claims Filed against Takeda Pharmaceuticals
6. Actos Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Federal Actos Litigation
7. Over 2,500 Cases Now Filed in Federal Actos Lawsuit Litigation; Case Management Conference Scheduled to Take Place on Thursday
8. Actos Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Conference in Federal Actos Litigation
9. Jury Rules Takeda Failed to Properly Warn a Patient and his Doctor Regarding Risks of Ingesting Diabetes Drug Actos; Parker Waichman LLP Responds
10. Actos Bladder Cancer Lawsuit: Bernstein Liebhard LLP Comments on Outcome of Nation’s Second Actos Lawsuit Trial
11. Actos Lawsuit News: Bernstein Liebhard LLP Comments on Start of Jury Deliberations in Actos Bladder Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... ... "I have gout, and I wanted to treat it naturally," said an ... relieve gout and pain caused by varicose veins. I drank it every morning for ... what VA doctors called the worst sinusitis case they'd seen and relieved gas, stress ...
(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, the ... the grand opening of the Sober College Robert Pfeifer Memorial Learning Center at ... 2-3, and was attended by an overwhelming amount of alumni, family, colleagues and ...
(Date:12/9/2016)... ... December 09, 2016 , ... Mediaplanet today announces distribution of the latest edition ... to sign up as an organ donor for the 123,000 people in the United ... donor can save up to 8 saves through organ donation and enhance many others ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... whiteboard display solutions, proudly announced today that a new solution for Emergency Departments ... fit in the tight space in Emergency Department examination rooms, and with a ...
(Date:12/9/2016)... ... December 09, 2016 , ... The ... Cable Network (PCN) during the summer of 2016. The program was made possible ... the United States Department of Health and Human Services Administration. The broadcast, ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Mitsubishi Tanabe Pharma Corporation (Head Office: ... Dr. Masayuki Mitsuka ) has presented data that ... intravenously in 10-14 day cycles for 48 weeks experienced ... Functional Rating Scale-Revised (ALSFRS-R). The data were presented at ... Dublin, Ireland . In ...
(Date:12/9/2016)... , Dec 9, 2016 Research and Markets ... 2016-2020" report to their offering. ... The global travel vaccines market to grow ... The report covers the present scenario and the growth prospects of ... size, the report considers the revenue generated from the sales of ...
(Date:12/9/2016)...  Forge Therapeutics, Inc. today announced a strategic ... TecDAX, ISIN: DE0005664809) to advance its novel Gram-negative ... bacterial infections including those caused by drug resistant ... antibacterial target for more than the past 15 ... points has hampered its progress. Forge has been ...
Breaking Medicine Technology: